Merck & Co in $2.7bn cancer research acquisition

Merck & Co has announced its acquisition of biotechnology company ArQule in a $2.7 billion deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Masimo keeps $634m smartwatch award and moves to appeal

21 July 2026 Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.

Biotech

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

20 July 2026 The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.

Biotech

Illumina ordered to recall products after German patent ruling

16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.

More features

K&L Gates expands European practice with Munich team hire

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

Arnold & Porter adds firepower to ITC practice with new partner hire

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

European court strikes down hearing aid sensor patent

Where Big Pharma is betting big in the M&A boom

Merck & Co in $2.7bn cancer research acquisition

More on this story

Editor's picks

Editor's picks

More features